BusinessHorizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis CommunityBy Nasdaq OMXJan 30, 2018, 1:30 PM UTC
BusinessHorizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic CystinosisBy Nasdaq OMXDec 27, 2017, 1:00 PM UTC
BusinessHorizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of AgeBy Nasdaq OMXNov 4, 2017, 3:00 PM UTC
BusinessRaptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis PatientsBy Nasdaq OMXSep 7, 2016, 7:30 AM UTC
BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical to Participate in the Cowen and Company 36th Annual Health Care ConferenceBy Nasdaq OMXMar 1, 2016, 12:30 PM UTC
BusinessRaptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy ActivitiesBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
